
Background & Aims: Chronic HBV infection persists because of the dysfunction of virus-specific CD8 + T cells. High HBV antigen levels impair the success of therapeutic vaccination. The influence of viral titers on vaccine-induced immunity remains to be fully elucidated. We compared the kinetics of vaccine responses in low- and high-titer HBV carrier mice to identify tipping points and dissect the decisive steps determining the outcome of therapeutic vaccination. Methods: We established low- and high-titer persistent HBV replication in the livers of immunocompetent C57BL/6J mice using adeno-associated-virus (AAV)-HBV and administered TherVacB , a heterologous protein prime/modified vaccinia Ankara boost vaccine. Serum and liver samples were collected during vaccination and subsequently longitudinally to analyze HBV-specific immune responses and viral parameters. Results: HBV antigen levels before vaccination did not significantly influence the hepatitis B surface antibody (anti-HBs) response ( p >0.9); however, they had a significant effect on the vaccine-induced CD8 T-cell response. TherVacB induced activated core-specific CD8 + T cells that efficiently infiltrated the liver in low- and high-titer HBV carriers. Low-titer HBV carrier mice achieved sustained viral clearance and memory T-cell formation, whereas high-titer mice exhibited only transient viral reduction, followed by CD8 + T-cell dysfunction and failure to clear the infection. The persistence of HBV infection and constant exposure to high antigen levels led to the overexpression of exhaustion markers, such as PD-1 and TOX ( p <0.01), as well as the co-stimulatory receptor 4-1BB ( p <0.01). Core-specific CD8 + T cells remained trapped in the liver, progressively lost their effector function, and were eventually eliminated. Conclusions: These findings identify critical time points that influence vaccine-induced CD8 T-cell responses, suggesting that early intervention targeting T-cell dysfunction may enhance therapeutic vaccination outcomes in chronic HBV infection. Impact and implications: This study demonstrates that baseline HBV antigen load critically determines the durability of vaccine-induced CD8 + T-cell immunity. Although therapeutic vaccination initially elicited liver-infiltrating, HBV-specific CD8 + T cells irrespective of the viral titer, only low-titer infection permitted sustained viral clearance and memory T-cell formation. In high-titer HBV carriers, persistent antigen exposure drove progressive T-cell exhaustion and deletion, resulting in transient viral control and treatment failure. Importantly, the data identify a critical time window in which early intervention to prevent or reverse T-cell dysfunction may be decisive. Clinically, these findings support combining therapeutic vaccination with antigen-lowering or immunomodulatory strategies applied early to achieve durable immune control in chronic HBV infection.
Background & Aims: First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase III CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMate 459. Methods: Archival or fresh tumor samples were collected before treatment and subjected to whole-exome sequencing, whole-transcriptome RNA sequencing, immunohistochemistry, and serological testing. Biomarkers were examined for associations with clinical outcomes (ORR by blinded independent central review [BICR] per RECIST v1.1, progression-free survival [PFS] by BICR, and OS). Results: The minimum follow-up was 33.6 months. In the nivolumab arm, 201, 230, 343, and ≥293 patients were evaluable by whole-exome sequencing, RNA sequencing, immunohistochemistry, and serology, respectively; 199, 239, 334, and ≥279 patients were evaluable in the sorafenib arm, respectively. Baseline tumor mutational burden was not predictive of survival with nivolumab. OS with sorafenib was improved in patients with mutated vs . wild-type Wnt/β-catenin pathway; consequently, OS was improved with nivolumab vs. sorafenib in patients with unaltered Wnt/β-catenin pathway (hazard ratio [HR] 0.66; 95% CI 0.47-0.91). High T-cell inflammation gene signature score and tumors with high programmed death ligand 1 levels (combined positive score ≥10) were associated with improved OS with nivolumab vs. sorafenib (HR 0.68; 95% CI 0.47-0.98 and HR 0.55; 95% CI 0.33-0.93, respectively); PFS and ORR were also improved. Among circulating blood biomarkers, high interferon-γ, low pro-collagen 11, and low frequency of granulocytic myeloid-derived suppressor cells were associated with improved nivolumab efficacy vs . sorafenib. Conclusions: These exploratory analyses from CheckMate 459 identified several candidate biomarkers that may be associated with the efficacy of first-line nivolumab vs. sorafenib and support further studies to identify patients with advanced HCC who may benefit from programmed death 1 inhibition. Impact and implications: Nivolumab demonstrated a higher objective response rate and favorable safety profile as first-line treatment compared with sorafenib for patients with advanced HCC in the CheckMate 459 trial, yet did not show a significant improvement in overall survival. The exploratory analyses presented here have identified several candidate biomarkers that may be associated with the efficacy of nivolumab vs. sorafenib in the first-line setting. These findings support additional studies to identify patients who may benefit from programmed death 1 inhibition. Clinical trial number: NCT02576509.
BACKGROUND AND AIMS A global international Delphi consensus of MASLD experts prioritised patient education and awareness as a key research domain, explicitly calling for population-based surveys to quantify knowledge gaps and guide targeted interventions. Commissioned by the EpaC ETS patient association, this study described patients' characteristics regarding MASLD awareness and health literacy. Secondary aim was to assess the psychometric properties and construct structure of the survey instrument. METHODS This cross-sectional study enrolled 460 Italian adults with self-reported physician-diagnosed MASLD. The eight-domain questionnaire covered disease awareness, nomenclature familiarity, diagnostic pathway, follow-up, treatment knowledge, lifestyle adherence, supplement and pharmacotherapy use, and economic burden. Psychometric validation of 40 Likert items employed exploratory and confirmatory factor analysis and MIMIC modelling. RESULTS Pre-diagnostic awareness was strikingly low: 59.8% had never heard of MASLD; familiarity with current nomenclature was negligible (MASLD 8.5%, MASH 9.8%). Critical misconceptions included failure to recognise diabetes as a risk factor (43.5%), belief that transaminases are always elevated (41.5%), and that disease progression requires elevated ALT (51.5%). Symptom burden was high and significantly greater in women across all domains (p<0.001). Despite appropriate physician counselling, three in four patients (75.7%) did not meet the recommended >= 150 min/week and 26.1% were entirely inactive. Supplements were used by 27.6%, largely self-prescribed; pharmacotherapy by 11.7%, of whom 50.0% received ursodeoxycholic acid - not guideline-recommended. Direct economic burden affected 64.6% of patients. Psychometric validation identified five latent dimensions (symptom burden, disease knowledge, reversibility beliefs, lifestyle efficacy beliefs, extrahepatic risk awareness) with acceptable model fit (CFI=0.917, RMSEA=0.069) and good-to-excellent reliability (omega 0.79-0.93). MIMIC modelling showed that symptom burden was driven by female sex and by depression, while cognitive dimensions were determined primarily by educational attainment and, to a lesser extent, by obesity. CONCLUSIONS Italian patients with self-reported physician diagnosis of MASLD harbour profound educational deficits, a marked attitude-practice gap, and partly guideline-discordant pharmacotherapy. The five-domain instrument provides a candidate framework for stratified educational interventions, for which external validation in an independent cohort is a prerequisite. IMPACT AND IMPLICATIONS A global Delphi consensus of MASLD experts identified patient education and awareness as a priority research domain and explicitly called for population-based surveys to quantify knowledge gaps, yet patient-level European data remain scarce; this study addresses that gap by assessing awareness, nomenclature familiarity, treatment knowledge, lifestyle behaviour and economic burden within a single national cohort, and by exploring the latent structure underlying patient knowledge. These results matter to hepatologists, primary care physicians, patient associations and policymakers, because they show that a formal diagnosis does not by itself transfer knowledge: misconceptions about diabetes as a risk factor and about the meaning of normal transaminases were widespread, lifestyle counselling was poorly translated into behaviour, and supplement use was frequent and largely self-prescribed. Practically, these findings support routine correction of these two misconceptions at the point of care, a direct question on over-the-counter and herbal products during the MASLD consultation, screening for depression within MASLD care pathways, and educational materials stratified by educational attainment and delivered through the digital and AI-based channels that patients actually use. Because participants were recruited through a patient association and MASLD status was self-reported, the deficits observed here should be regarded as conservative, and the five-domain instrument requires external validation in an independent, unselected and objectively characterised cohort before applied use.